Skip to content
Sign in
Myomo logo
RoboticsPublic

Myomo

catalyst in 5dNo base rate yet — MYO has 0 graded prints on the record, and the bar is 3.Website
Ticker
MYO
Beat
robotics
Size
Public Company
Revenue
$11.7M
as of Jun 2026
Cash
$11.2M
as of Jun 2026
Burn
$2.0M/qtr
as of Jun 2026
Runway
~1.4yr at this rate
as of Jun 2026
Researched · Stale
10 days ago

A category-of-one reimbursed medical-robotics razor (myoelectric arm orthosis, 6.3M-stroke US TAM) finally pivoting from cash-burning ad-funded patient acquisition to lower-cost recurring referrals — but it must prove the operating-leverage turn at ~$45M revenue before the Avenue debt covenants and a sub-$1.50 stock force another dilutive raise; bullish on the model, watching the proof.

Orbit · who it trades with and competes with
1 on the rings · 0 trade · 1 rival
2 mentions across our dossiers
Focus · Robotics
Myomo
MYO · public
No published house view
Competes with
Links · 1 company · 0 trade · 1 rival
“- Competitors (Lifeward/ReWalk 7, Ekso Indego Personal, Wandercraft's self-balancing "Eve," Myomo, Chinese entrants) are converging; some are pushing into the personal/home market and FDA personal-use clearance — a vector where HAL's clini…”Cyberdyne · RIVAL · from Cyberdyne’s dossier
TholoBbrief←→step through the orbitESCcloseclick a company to open ittap a company to read it, tap again to open it
Price

Weekly closes

MYO · weekly close
1.24 USD+2.5%
Friday 30 Oct 2026 · last 52 Fridays 0.67–1.73
pick a pin
Every pin is a dated row
Solid: filed with the SEC, settled at FINRA, or a recorded split. Hollow: the scheduled print, past the last close, never a price.
Height is the close · the ribbon is the stored record, a missing week a missing point · a pin stands on its Friday
  1. Insiders sold, 90 days: 15,488 sh · 1 filing, Form 4 · 11 Sept 2026
  2. Short interest: 1,064,143 sh · 3.85 days to cover, FINRA · settled 15 Oct 2026
  3. Insiders bought, 90 days: 441,502 sh · 6 filings, Form 4 · 13 Oct 2026
  4. Next print: in 5 days, Scheduled · 8 Nov 2026, scheduled
1.24USD+2.5%robotics -1.6%MYO · 112 weekly closes to 2026-10-30

Who is buying

Insiders sold, last 90 daysSEC Form 4 · newest 11 Sept 2026
1 filing · 15,488 shares
Insiders bought, last 90 daysSEC Form 4 · newest 13 Oct 2026
6 filings · 441,502 shares
Shares sold shortFINRA · settled 15 Oct 2026
1,064,143 shares
Days to unwind the shortFINRA · settled 15 Oct 2026
3.85
see the whole series
Financials

The reported figures

Revenue · quarterly
$11.7M
latest, Q2 ’26 · 12 periods stored
Filed · primary
Q2 ’26
$11.7M USD
as of 30 Jun 2026
Source: sec.gov
Solid = filed (primary) · hollow dashed = estimate · a dashed floor tick is a period with no figure held · quarterly and annual never share an axis
Myomo, quarterly figures held, Q3 ’23 to Q2 ’26
PeriodAs ofRevenueOperating marginFree cash flowCapexCashShares outstandingGradingSource
Q3 ’2330 Sept 2023$5.1M USD-39.9% share of revenue-$1.8M USD$54K USD$6.9M USD26.5M sharesFiled · primarysec.gov
Q4 ’2331 Dec 2023$4.8M USD-51.2% share of revenue-$2.4M USD$32K USD$6.9M USD—Filed · primarysec.gov
Q1 ’2431 Mar 2024$3.8M USD—-$3.3M USD$60K USD$5.4M USD28.5M sharesFiled · primarysec.gov
Q2 ’2430 Jun 2024$7.5M USD-14.8% share of revenue-$2.0M USD$119K USD$5.8M USD30.2M sharesFiled · primarysec.gov
Q3 ’2430 Sept 2024$9.2M USD-10.4% share of revenue-$1.8M USD$321K USD$6.6M USD30.2M sharesFiled · primarysec.gov
Q4 ’2431 Dec 2024$12.1M USD-2.0% share of revenue$2.5M USD$860K USD$24.4M USD—Filed · primarysec.gov
Q1 ’2531 Mar 2025$9.8M USD-35.8% share of revenue-$3.3M USD$671K USD$19.8M USD34.4M sharesFiled · primarysec.gov
Q2 ’2530 Jun 2025$9.7M USD-47.6% share of revenue-$9.1M USD$221K USD$14.2M USD37.8M sharesFiled · primarysec.gov
Q3 ’2530 Sept 2025$10.1M USD-34.9% share of revenue-$3.9M USD$2.1M USD$12.6M USD38.4M sharesFiled · primarysec.gov
Q4 ’2531 Dec 2025$11.4M USD-24.4% share of revenue$98K USD-$1.2M USD$14.1M USD—Filed · primarysec.gov
Q1 ’2631 Mar 2026$10.1M USD-31.2% share of revenue-$2.5M USD$328K USD$11.4M USD38.5M sharesFiled · primarysec.gov
Q2 ’2630 Jun 2026$11.7M USD-19.3% share of revenue-$2.0M USD$32K USD$11.2M USD39.6M sharesFiled · primarysec.gov

Myomo’s figures as the company reported them in its filings. Quarters are calendar quarters, so a company whose year ends in January shows each fiscal quarter under the calendar quarter it falls in. An empty slot is a quarter we hold no figure for.

Revenue · quarterlyQ3 ’23 – Q2 ’26
$11.7M+21% vs Q2 ’25

Q2 ’26 · as of Jun 2026

Revenue Q3 ’23: $5.1M, as of Sep 2023Revenue Q4 ’23: $4.8M, as of Dec 2023Revenue Q1 ’24: $3.8M, as of Mar 2024Revenue Q2 ’24: $7.5M, as of Jun 2024Revenue Q3 ’24: $9.2M, as of Sep 2024Revenue Q4 ’24: $12.1M, as of Dec 2024Revenue Q1 ’25: $9.8M, as of Mar 2025Revenue Q2 ’25: $9.7M, as of Jun 2025Revenue Q3 ’25: $10.1M, as of Sep 2025Revenue Q4 ’25: $11.4M, as of Dec 2025Revenue Q1 ’26: $10.1M, as of Mar 2026Revenue Q2 ’26: $11.7M, as of Jun 2026
Operating margin · quarterlyQ3 ’23 – Q2 ’26
-19.3%+28.3 pts vs Q2 ’25

Q2 ’26 · as of Jun 2026

Operating margin Q3 ’23: -39.9%, as of Sep 2023Operating margin Q4 ’23: -51.2%, as of Dec 2023Operating margin Q2 ’24: -14.8%, as of Jun 2024Operating margin Q3 ’24: -10.4%, as of Sep 2024Operating margin Q4 ’24: -2.0%, as of Dec 2024Operating margin Q1 ’25: -35.8%, as of Mar 2025Operating margin Q2 ’25: -47.6%, as of Jun 2025Operating margin Q3 ’25: -34.9%, as of Sep 2025Operating margin Q4 ’25: -24.4%, as of Dec 2025Operating margin Q1 ’26: -31.2%, as of Mar 2026Operating margin Q2 ’26: -19.3%, as of Jun 2026

A margin beyond ±100%, or on zero revenue, is left out as not meaningful.

Free cash flow · quarterlyQ3 ’23 – Q2 ’26
-$2.0M

Q2 ’26 · as of Jun 2026

Free cash flow Q3 ’23: -$1.8M, as of Sep 2023Free cash flow Q4 ’23: -$2.4M, as of Dec 2023Free cash flow Q1 ’24: -$3.3M, as of Mar 2024Free cash flow Q2 ’24: -$2.0M, as of Jun 2024Free cash flow Q3 ’24: -$1.8M, as of Sep 2024Free cash flow Q4 ’24: $2.5M, as of Dec 2024Free cash flow Q1 ’25: -$3.3M, as of Mar 2025Free cash flow Q2 ’25: -$9.1M, as of Jun 2025Free cash flow Q3 ’25: -$3.9M, as of Sep 2025Free cash flow Q4 ’25: $98K, as of Dec 2025Free cash flow Q1 ’26: -$2.5M, as of Mar 2026Free cash flow Q2 ’26: -$2.0M, as of Jun 2026

Operating cash flow minus capital spending.

Cash · quarterlyQ3 ’23 – Q2 ’26
$11.2Mdebt $11.5M

Q2 ’26 · as of Jun 2026

Cash Q3 ’23: $6.9M, as of Sep 2023Cash Q4 ’23: $6.9M, as of Dec 2023Cash Q1 ’24: $5.4M, as of Mar 2024Cash Q2 ’24: $5.8M, as of Jun 2024Cash Q3 ’24: $6.6M, as of Sep 2024Cash Q4 ’24: $24.4M, as of Dec 2024Cash Q1 ’25: $19.8M, as of Mar 2025Cash Q2 ’25: $14.2M, as of Jun 2025Cash Q3 ’25: $12.6M, as of Sep 2025Cash Q4 ’25: $14.1M, as of Dec 2025Cash Q1 ’26: $11.4M, as of Mar 2026Cash Q2 ’26: $11.2M, as of Jun 2026Debt Q4 ’24: $11.2M, as of Dec 2024Debt Q2 ’25: $1.3M, as of Jun 2025Debt Q3 ’25: $2.4M, as of Sep 2025Debt Q4 ’25: $11.2M, as of Dec 2025Debt Q1 ’26: $10.9M, as of Mar 2026Debt Q2 ’26: $11.5M, as of Jun 2026

CashDebt

Shares outstanding · quarterlyQ3 ’23 – Q2 ’26
39.6M+49% since Q3 ’23

Q2 ’26 · as of Jun 2026

Shares outstanding Q3 ’23: 26.5M, as of Sep 2023Shares outstanding Q1 ’24: 28.5M, as of Mar 2024Shares outstanding Q2 ’24: 30.2M, as of Jun 2024Shares outstanding Q3 ’24: 30.2M, as of Sep 2024Shares outstanding Q1 ’25: 34.4M, as of Mar 2025Shares outstanding Q2 ’25: 37.8M, as of Jun 2025Shares outstanding Q3 ’25: 38.4M, as of Sep 2025Shares outstanding Q1 ’26: 38.5M, as of Mar 2026Shares outstanding Q2 ’26: 39.6M, as of Jun 2026

A rising count is dilution: each existing share owns less of the company.

Latest filing: sec.gov

The record

What happened

What happened
DateTypeWhat happenedSource
2026-10-24editorial noteSources added: 0 → 3The dossier's cited-link count grew from 0 to 3 (deep-dive-2026-06-20.md → deep-dive-2026-10-24.md).dossier
2026-10-24editorial noteMargin figure revised: 68.2% → 72.1%Margin moved from 68.2% (deep-dive-2026-06-20.md) to 72.1% (deep-dive-2026-10-24.md).dossier
2026-10-24editorial noteRevenue figure revised: 20% → $11.7MRevenue moved from 20% (deep-dive-2026-06-20.md) to $11.7M (deep-dive-2026-10-24.md).dossier
2026-10-15filingMyomo: 4 insiders file Form 4s for RSU grants, 9-15 OctFour insiders filed Form 4s: RSU grants to Kovelman (32,500), Henry (51,250 and 6,272), Gudonis (71,250 and 8,363) and McClure (275,000 inducement grant); Henry disposed of 3,133 shares at $1.37 for taxes. No open-market purchases.agent:company-events · SEC EDGAR Form 4
2026-10-13filingForm 4 cluster: 3 officers, RSU grants 9 and 12 Oct 2026RSU grants: Henry (CFO) 6,272 and Gudonis (CEO) 8,363 on 9 Oct; McClure (Chief Commercial Officer) 275,000 inducement RSUs on 12 Oct. Henry had 3,133 sh withheld for tax at $1.37.agent:company-events · SEC EDGAR Form 4
dossier age
10 days
researched 24 Oct 2026 · ring fills at 180
pick a section
Each column is a section of the dossier
Its height is how many times the section names a filing: 11 mentions across 2 sections. A dashed foot names none.
Primary sources
0 of 2 sections name no filing · Enter steps through them
  1. The dossier: Refresh delta (since 2026-06-20), 435 words, 8 filing mentions
  2. The dossier: What held, 63 words, 3 filing mentions
Research

The Myomo dossier

The verdict

A category-of-one reimbursed medical-robotics razor (myoelectric arm orthosis, 6.3M-stroke US TAM) finally pivoting from cash-burning ad-funded patient acquisition to lower-cost recurring referrals — but it must prove the operating-leverage turn at ~$45M revenue before the Avenue debt covenants and a sub-$1.50 stock force another dilutive raise; bullish on the model, watching the proof.

Primary sources

SEC filings

Source documents — open to read in full

Refresh delta (since 2026-06-20)

  1. Q2 results. Revenue $11.7M, up 21% year on year, above expectations. Gross margin 72.1% (Q2 2025: 62.7%). Operating loss $2.3M (Q2 2025: $4.6M). Net loss $4.0M, or $0.09 per share, including a $1.2M non-cash mark-to-market charge on derivative liabilities (Q2 2025: $4.6M). Adjusted EBITDA loss $0.8M against $4.0M, about a 79% improvement. Operating expenses rose less than 1%. [sec.gov: Form 8-KA filing for something that happened between reports and matters enough to tell shareholders now. filed 2026-08-05, exhibit 99.1, https://www.sec.gov/Archives/edgar/data/1369290/000119312526335109/myo-ex99_1.htm; quarter ended 2026-06-30]
  2. Operating metrics. A record 255 orders, up 23% year on year; 739 patients added to the pipeline; average selling price about $55,500, up 2%. 53% of Q2 revenue came from recurring patient sources such as provider referrals, orthotic and prosthetic partners and the VA (Q2 2025: 26%). In-network access, including Medicare and the VA, exceeds 100 million covered lives. [sec.gov: 8-K filed 2026-08-05, exhibit 99.1, same URL]
  3. Guidance. Full-year 2026 revenue guidance raised to $45M to $47M. Q3 2026 revenue expected at $11.5M to $12.0M, up 14% to 19% year on year, with modestly higher sequential operating expenses. [sec.gov: 8-K filed 2026-08-05, exhibit 99.1, same URL]
  4. Clinical and product. The University of Utah randomised controlled trial has enrolled 25 of a planned 50 subjects; MyoPro 3 development continues, and a hand-only prototype for the German market was shown in May. [sec.gov: 8-K filed 2026-08-05, exhibit 99.1, same URL]
  5. Shares and authorised capital. 39,607,854 common shares outstanding at 2026-07-31. At the 2026-06-25 annual meeting stockholders approved an amendment raising authorised common stock to 100,000,000 shares (effective on filing 2026-06-25), approved an amendment to the equity plan, and re-elected Paul R. Gudonis and Thomas F. Kirk as Class III directors; 38,638,669 shares were outstanding and entitled to vote at the 2026-04-29 record date. [sec.gov: Form 10-QThe quarterly version of the annual report. Lighter, and not audited. filed 2026-08-05, https://www.sec.gov/Archives/edgar/data/1369290/000119312526335149/myo-20260630.htm; 8-K filed 2026-06-26, https://www.sec.gov/Archives/edgar/data/1369290/000119312526285450/myo-20260625.htm]
  6. Convertible loan terms. The 10-Q says the lender has the right to convert up to $3.0M of Tranche 1 principal and up to $1.0M of Tranche 2 principal into common stock. [sec.gov: 10-Q filed 2026-08-05, same URL as item 5]
  7. Where the new filings meet the carried view (stated as fact, no line changed). The carried seed catalyst "Q2 2026 print vs $10.3–10.8M guide + opex-leverage proof" meets items 1 and 2: revenue of $11.7M exceeded the top of that range, and operating expenses rose under 1%. The carried catalyst "FY2026 tracking to $43–46M" meets item 3: guidance is now $45M-$47M. The carried catalyst on a "capital event" and "NYSE American $1 listing/reverse-split risk" meets item 5, which shows the authorised share count raised to 100,000,000. The carried seed's price figures rest on market data this delta does not refresh.

What held

  • The company still sells a single wearable-robotics product line, reimbursed through Medicare, the VA and commercial payers, with ASP of about $55,500. [sec.gov: 8-K filed 2026-08-05, exhibit 99.1]
  • It remains loss-making: Q2 operating loss $2.3M and net loss $4.0M. [sec.gov: 8-K filed 2026-08-05, exhibit 99.1]
  • Order growth continued: a record 255 orders in Q2. [sec.gov: 8-K filed 2026-08-05, exhibit 99.1]

How our view changed

2 dossiers

Every dossier we have written on Myomo, newest first.

  1. current

    A category-of-one reimbursed medical-robotics razor (myoelectric arm orthosis, 6.3M-stroke US TAM) finally pivoting from cash-burning ad-funded patien…

  2. A category-of-one reimbursed medical-robotics razor (myoelectric arm orthosis, 6.3M-stroke US TAM) finally pivoting from cash-burning ad-funded patien…

Company details

IndustryRobotics
SizePublic Company
WebsiteVisit Myomo

Others in robotics

5 names

Where Myomo sits against the other names we cover on this beat. Each line is that company’s verdict, not a summary of it.